An Activation-Specific Platelet Inhibitor That Can Be Turned On/Off by Medically Used Hypothermia
Author(s) -
Denijal Topcic,
Wookhyun Kim,
Jessica K. Holien,
Fu Jia,
Paul C. Armstrong,
Jan David Hohmann,
Andreas Straub,
Guy Y. Krippner,
Carolyn A. Haller,
Helena Domeij,
Christoph E. Hagemeyer,
Michael W. Parker,
Elliot L. Chaikof,
Karlheinz Peter
Publication year - 2011
Publication title -
arteriosclerosis thrombosis and vascular biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.007
H-Index - 270
eISSN - 1524-4636
pISSN - 1079-5642
DOI - 10.1161/atvbaha.111.226241
Subject(s) - hypothermia , extracorporeal circulation , medicine , pharmacology , drug , elastin , platelet activation , in vivo , platelet , immunology , anesthesia , biology , pathology , microbiology and biotechnology
Therapeutic hypothermia is successfully used, for example, in cardiac surgery to protect organs from ischemia. Cardiosurgical procedures, especially in combination with extracorporeal circulation, and hypothermia itself are potentially prothrombotic. Despite the obvious need, the long half-life of antiplatelet drugs and thus the risk of postoperative bleedings have restricted their use in cardiac surgery. We describe here the design and testing of a unique recombinant hypothermia-controlled antiplatelet fusion protein with the aim of providing increased safety of hypothermia, as well as cardiac surgery.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom